Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
2007-02-06
2007-02-06
Chan, Christina (Department: 1644)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C435S372000, C435S372300
Reexamination Certificate
active
10144188
ABSTRACT:
Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo. In contrast, CTL induced by antigenic peptides derived from IgE specifically inhibit IgE responses, and adoptive transfer of CD40L-specific CTL to NOD mice at early age delay the development of diabetes in NOD mice. In vitro generated CTL specific for non-tumor self-antigens expressed on activated CD4 T cells regulate immune responses in vivo.
REFERENCES:
patent: 5614611 (1997-03-01), Chang
patent: 6228621 (2001-05-01), Williams et al.
patent: WO 9402156 (1994-02-01), None
patent: WO 0023053 (2000-04-01), None
patent: WO0023053 (2000-04-01), None
patent: WO 0025722 (2000-05-01), None
Latouche et al., Nature Biotechnology, Apr. 2000, vol. 18, pp. 405-409.
Goldsby et al., Immunology, Fifth edition, Freeman and Company, New York, 2003, pp. 9-21 and 362-365.
Sprent et al., “Constructing Artificial Antigen-Presenting Cells From Drosophila Cells”,Advances in Experimental Medicine And Biology, vol. 417, pp. 249-254 (1997).
Flesch et al., “Monocyte inflammatory protein-1alpha facilities priming of CD8=T cell responses to exogenous viral antigen”, Int. Immunol., vol. 12, No. 9, pp. 1365-1370, 2000.
Alters et al., “Immunotherapy of cancer: Generation of CEA specific CTL using CEA peptide pulsed dendritic cells”, Dendritic cells in Fundamental and Clinical Immunology, vol. 417, pp. 519-524, 1997.
Wentworth et al., “In vitro induction of primary, antigen-specific CTL from human peripheral blood mononuclear cells sumulated with synthetic peptides”, Mol Immunol., vol. 32, No. 9, pp. 603-612, 1995.
Gagliardi et al., “Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro”, Int. Immunol., vol. 7, No. 11, pp. 1741-1752, 1995.
Cai Zeling
DeGraw Juli
Jackson Michael R.
Kong Yan
Peterson Per A.
Belyavskyi Michail A.
Chan Christina
Ortho-McNeil Pharmaeutical, Inc.
Woodcock & Washburn LLP
LandOfFree
Isolated CD8 + T lymphocytes specifically cytotoxic for a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolated CD8 + T lymphocytes specifically cytotoxic for a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolated CD8 + T lymphocytes specifically cytotoxic for a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3816388